News |
| 2004 | 2005 | 2006 | 2007 | 2008 |
To receive news and updates via email join our mailing list. click here
| Date | Press Releases | |
|---|---|---|
|
12/12/2006 |
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-cell lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
--Complete clinical responses and significant pruritus relief reported with single-agent
romidepsin--
|
|
|
12/12/2006 |
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for Peripheral T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
--Durable complete responses observed in various subtypes of peripheral T-cell lymphoma
(PTCL) with single-agent romidepsin--
|
|
|
12/04/2006 |
Gloucester Pharmaceuticals Announces Presentation of Romidepsin Data for T-cell Lymphomas at the 2006 American Society of Hematology (ASH) Annual Meeting
--Data from over 100 patients in ongoing cutaneous T-cell lymphoma (CTCL) and peripheral
T-cell lymphoma (PTCL) studies to be presented--
|
|
|
10/04/2006 |
Gloucester Presents Update on Phase II Trial in Metastatic Hormone Refractory Prostate Cancer at the 31st ESMO Congress
--Interim data show single agent activity reported in metastatic hormone refractory prostate
cancer--
|
|
|
9/12/2006 |
Gloucester Pharmaceuticals Initiates Phase I/II Clinical Study in Pancreatic and Other Advanced Solid Tumors
--Combination trial will investigate romidepsin (depsipeptide) in combination with gemcitabine--
|
|
|
6/06/2006 |
Positive Interim Results for Gloucester Pharmaceutical's Pivotal Trial of Depsipeptide Reported at the 2006 Annual Meeting of The American Society of Clinical Oncology
--36% overall response rate in patients with cutaneous T-cell lymphoma; results consistent with previously reported studies--
|
|
|
6/01/2006 |
Gloucester Pharmaceuticals Appoints Jean C. Nichols, Ph.D., Executive Vice President and Chief Scientific Officer
|
|
|
5/30/2006 |
Gloucester Pharmaceuticals to Present Interim Pivotal Clinical Trial Data at the 2006 Annual Meeting of The American Society of Clinical Oncology
|
|
|
4/26/2006 |
Data Safety Monitoring Board Recommends Continuation of Gloucester Pharmaceuticals' Pivotal Trial for Depsipeptide in Cutaneous T-Cell Lymphoma
--Second Favorable Recommendation from DSMB--
|
|
|
4/05/2006 |
Gloucester Pharmaceuticals Reports on Preclinical Study of Depsipeptide in Pancreatic Cancer from the 97th Annual Meeting of The American Association of Cancer Research
--Significant preclinical activity seen for depsipeptide in combination with gemcitabine--
|
|
|
3/14/2006 |
Gloucester Pharmaceuticals Announces Expansion of Pivotal Trial of Depsipeptide in Cutaneous T-Cell Lymphoma
--Clinical sites now include major medical centers in US--
|
|
|
3/1/2006 |
Gloucester Pharmaceuticals Reports on Phase 2 Clinical Study Presented at the 2006 Prostate Cancer Symposium
--Depsipeptide shown to have clinical activity in hormone refractory prostate cancer--
|
|